Healey Don 4

What Happened

• Don Healey, Chief Technology Officer of Adicet Bio, was granted 43,361 shares as an award (reported as a derivative acquisition) on 2026-03-25. The shares were reported at $0.00 per share (no cash was paid), so there is no immediate purchase value. This is a compensation grant rather than a market buy or sale.

Key Details

• Transaction date: 2026-03-25; Form 4 filed: 2026-03-27 (timely — two business days after the transaction).
• Transaction type/code: Award/Grant (reported as A, derivative acquisition).
• Shares granted: 43,361; reported price: $0.00 (no cash exchanged).
• Vesting: 1/48th of the shares vest on each of the next 48 monthly anniversaries of the grant date, subject to continued service (per footnote).
• Shares owned after the transaction: not specified in the filing.
• No indication of immediate sale, tax withholding, or a 10b5-1 plan in this filing.

Context

• This appears to be a standard time‑based equity award for an executive, intended for compensation and retention. Because the award vests over four years, the shares are not freely tradable immediately and do not reflect an immediate market purchase or sale. Such grants are common and are informational rather than a direct bullish or bearish signal.